Navigation Links
Avalere Examines Emerging Strategies for Managing Imaging Utilization
Date:7/11/2008

WASHINGTON, July 11 /PRNewswire/ -- Efforts and initiatives designed to improve the utilization of advanced medical imaging services are increasing, says a new report released today by Avalere Health. The report comes at a time when healthcare leaders and policymakers are actively exploring how to help patients access advanced imaging services while assuring high-quality, cost-effective diagnosis and treatment.

Avalere's new report highlights approaches used by physicians, health insurers, and equipment manufacturers to help doctors offer their patients appropriate and efficient imaging services. The report's authors focused primarily on three sets of approaches -- updated and more comprehensive appropriateness guidelines; enhanced accreditation and certification programs; and expanded education and training -- with a lens toward how these programs can influence provider behavior, imaging quality, and patient care.

"We're seeing a new level of forward-leaning engagement by payors and physicians to get the right image for the right patient by the right doctor in the right setting of care," said Jon Glaudemans, senior vice president of Avalere and co-author of the report. "These new, more holistic approaches that extend beyond simple reimbursement strategies have the potential to improve the quality of advanced imaging care in tangible ways."

Some of the efforts profiled in the Avalere report seek to direct physicians to appropriate scans by providing new clinical guidelines at the point of care. For example, United HealthCare and the American College of Cardiology Foundation (ACCF) have a new pilot program to test ACCF's appropriateness criteria for SPECT-MPI, an advanced imaging technique. The program's new data-rich registry will track rates of appropriate, inappropriate, and uncertain scans while providing physicians with personalized feedback about their performance.

Payors' recent embrace and expansion of accreditation and cert
'/>"/>

SOURCE Avalere Health
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Avalere Study Shows Medicare Part D Helping People with Type 2 Diabetes; Warns People with Diabetes of Probability of Reaching the Donut Hole
2. Avalere Health Data Finds Four-Tier System Growing Among Medicare Part D Plans
3. Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File
4. Mailman School of Public Health study examines link between racial discrimination and substance use
5. First study examines newly-licensed RN work attitudes and intentions
6. New study examines brain-gut relationship in those suffering with stomach pain or discomfort
7. Research examines connection between substance abuse and violence
8. TV Documentary Examines Three Decades of Tobacco Politics, Policies and People in Minnesota
9. USC study examines effects of caregiving
10. Study examines ethnic differences in sleep quality and blood pressure
11. Quality of life study examines burden of epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... Brain perfusion application is accessible to cli...tion® thin-client system. , ... -- Ziosoft®, Inc. , a leader in advanced vis...ing , today announced that it has received 510(k) ...on (FDA) for its CT brain perfusion application. ...
(Date:1/7/2009)... By the time pancreatic cancer is discovered, it ...tor Patrick Swayze) and survival rates are low. D...zing in pancreatic, liver and gastrointestinal (GI...as created a groundbreaking team approach to impro...comes for patients. , M...
(Date:1/7/2009)... Insulet Corporation (Nasdaq: PODD ), the leader...lin Management System, today announced the company...ealthcare Conference. Management is scheduled to p... on January 14, 2009 at The Westin St. Francis in ...entation, material information concerning the Comp...
(Date:1/7/2009)...7 Robbins & Myers, Inc.,(NYSE: RBN ) today ...$0.50 for,its fiscal first quarter ended November ... first quarter. First quarter 2009 sales increase...lion, and orders decreased 5% to $185,million. Ex... currency,translation, organic sales increased 6% ...
Breaking Medicine News(10 mins):Health News:Ziosoft Receives FDA Clearance for CT Brain Perfusion Application 2Health News:Nationally-Recognized Pancreatic Cancer Surgeon Develops Unique Team Approach to Improve Patient Outcomes 2Health News:Robbins & Myers Announces First Quarter 2009 Results 2Health News:Robbins & Myers Announces First Quarter 2009 Results 3Health News:Robbins & Myers Announces First Quarter 2009 Results 4Health News:Robbins & Myers Announces First Quarter 2009 Results 5Health News:Robbins & Myers Announces First Quarter 2009 Results 6Health News:Robbins & Myers Announces First Quarter 2009 Results 7Health News:Robbins & Myers Announces First Quarter 2009 Results 8Health News:Robbins & Myers Announces First Quarter 2009 Results 9
...colonoscopies are capable of detecting cancers in ...edicare's extension of coverage to include colonos...nical Scholars Program and Yale Medical School sai... medical coverage to include all categories and no...
...nounced that they have discovered a drug that will...pposedly blocks the sensation of a” euphoric high”...d hypothalamus, the part of the brain where orexin... induces euphoria. A compound that effectively blo...
...eriditis (SE) is present in eggs sometimes, and wh...ing properly cooked) are eaten, may cause illness....warns consumers to be aware of this bacteria and f...gg-related illness. Some holiday favorites, such...
...s who receive transfusions during heart bypass sur...y dangerous infections, and dying, after their ope...lain a longstanding medical mystery: why women byp...to die in the first few months after surgery. Wome...
Other Medicine News:Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 2Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 3
(Date:1/7/2009)...n. 7 Scientists have id...ikelihood of relapse in children with acute lympho...aution that further research is needed to determin...OS, lead to leukemia relapse, the findings are li...sts to assess the risk of treatment failure. By us...
(Date:1/7/2009)...d, January 7 Circassia Ltd, a spec...y and critical care, today,announced that followi...th,its ToleroMune(R) anti-allergy technology, the...r a further phase II clinical trial in cat allergy...ruited 120 patients with confirmed,cat allergies,...
(Date:1/6/2009)...n. 6 Sequella, Inc., a ...n diseases of epidemic potential, announced today ...ent of tuberculosis (TB), was the first drug appro...gram contract to Dynport Vaccine Company LLC and Q...he National Institute of Allergy and Infectious Di...
(Date:1/5/2009)... Jan. 5 Micromet, Inc.,...eloping novel, proprietary,antibodies for the tre...ases,provides an outlook on key events anticipat...to provide an update on its research and developme...April 12 to 16, 2009: Update on several preclinica...
Breaking Medicine Technology:Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Cardinal Health GE Healthcare Broaden Relationship to Offer Greater Access to Myoview 28TM 29 Imaging Agent 14581 1Cardinal Health GE Healthcare Broaden Relationship to Offer Greater Access to Myoview 28TM 29 Imaging Agent 14581 2Cardinal Health GE Healthcare Broaden Relationship to Offer Greater Access to Myoview 28TM 29 Imaging Agent 14581 3Cardinal Health GE Healthcare Broaden Relationship to Offer Greater Access to Myoview 28TM 29 Imaging Agent 14581 4Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvanias Uninsured 14579 1Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvanias Uninsured 14579 2Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvanias Uninsured 14579 3Transition Therapeutics to Present at Cowen 26 Company 28th Annual Healthcare Conference 14577 1Transition Therapeutics to Present at Cowen 26 Company 28th Annual Healthcare Conference 14577 2C1 Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema According to Pivotal Study 4050 1C1 Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema According to Pivotal Study 4050 2C1 Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema According to Pivotal Study 4050 3C1 Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema According to Pivotal Study 4050 4
...on highlights health care cost benefit of,bioengin...ire-FirstCall/ -- Cell,Therapeutics, Inc. (CTI) an...ting of the American Society of Clinical Oncology ...tilization (MRU) and,associated costs with XYOTAX ...itabine or vinorelbine in treating patients with,n...
...1 Phase III Study Results Presented At ASCO -- , C...tment with,pegylated interferon alfa-2b in stage I... on relapse-free survival (RFS),according to the ...ed in patients with stage III melanoma. Results of...tion for the Research and,Treatment of Cancer (EOR...
Other Medicine Technology:XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine,or Vinorelbine in Treating Non-Small Cell Lung Cancer 2XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine,or Vinorelbine in Treating Non-Small Cell Lung Cancer 3XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine,or Vinorelbine in Treating Non-Small Cell Lung Cancer 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5
Inquire
Adjustable speed vortex with inter-changeable heads, 110 V
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures.
Use the Mo Bio Vortex Adapter in conjunction with the Vortex Genie 2 for rapid bead beating procedures. Using the Mo Bio Vortex Adapter is an inexpensive alternative to other bead beating and Fast Pr
Medicine Products: